NASH

[Journal of Hepatology] Scientists describe the potential for chronopharmacology in non-alcoholic steatohepatitis (NASH), discuss how the major NASH drug candidates are influenced by circadian biology, and encourage greater consideration of the timing of drug administration in the design of future clinical trials.

[Proceedings of the National Academy of Sciences of the United States of America] The authors showed that TANK-binding kinase 1 (TBK1) served as a vital regulator of proinflammatory macrophage function and protected against tissue inflammation.

[89bio, Inc.] 89bio, Inc. announced positive topline results from an open-label expansion cohort of 20 patients in the Phase Ib/IIa proof-of-concept study evaluating pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).

[Nature Communications] Using hepatocyte-, hepatoblast- and ductal cell-derived organoids, investigators demonstrated that the differentiation defects and lipid alterations were, in part, cell-autonomous.

[Aligos Therapeutics, Inc.] Aligos Therapeutics, Inc. announced that it has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).

[Cell Chemical Biology] Scientists revealed a functional duality of the Irs2 gene locus, where reciprocal changes of Irs2 and ASIrs2 in obesity caused insulin resistance and steatosis.